COMMUNIQUÉS West-GlobeNewswire

Bicycle Health Grows Leadership Team to Further Expand Access to Opioid Use Disorder Care for Patients in the Criminal Justice System
14/10/2025
Steve Tomlin has decades of experience bringing opioid and substance use disorder care to criminal justice populations BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s largest provider of virtual [...]
Rendever Leads Expansion of Virtual Reality in Hospice Care
14/10/2025
The AgeTech company expands hospice partnerships to enhance end-of-life care with immersive experiences for patients and families BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in [...]
Imprivata Acquires Verosint to Add AI-Powered Risk Signaling to its Leading Enterprise Access Management Platform
14/10/2025
Integration of Verosint Identity Threat Detection & Response with Imprivata Enterprise Access Management will strengthen the company’s advanced and passwordless access strategy to bolster security, improve workflow [...]
ZymoChem Named Startup of the Year by The International Textile Manufacturers Federation
14/10/2025
SAN LEANDRO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ZymoChem , the materials company decarbonizing the chemical industry through biological manufacturing, announces its recognition as a Startup of the Year by The [...]
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
14/10/2025
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and [...]
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
14/10/2025
First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified stem cell therapy [...]
Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze
14/10/2025
– Parties enter into Restructuring Support Agreement; Vireo to bid to acquire control of Schwazze assets – – Schwazze operates 63 dispensaries and 10 manufacturing facilities in Colorado and New Mexico – MINNEAPOLIS, [...]
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence
14/10/2025
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision Oncology Initiatives BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc [...]
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
14/10/2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single- [...]
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
14/10/2025
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
14/10/2025
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the [...]
Assembly Biosciences Announces Upcoming Investor Conference Participation
14/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that [...]
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
14/10/2025
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
14/10/2025
AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients With over 100 surgeon partners and thousands of cases performed throughout the early-release program, Iantrek pioneers a new era in [...]
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
14/10/2025
Purespring Therapeutics to Present at Chardan’s 9 th Annual Genetic Medicines Conference London – 14 October 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney [...]
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
14/10/2025
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a [...]
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
14/10/2025
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a [...]
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
14/10/2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
14/10/2025
CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of [...]

Pages